At what AST‑to‑Platelet Ratio Index (APRI) values does a score >2.0 indicate cirrhosis, >0.7 indicate significant fibrosis, and below which level treatment is generally not indicated?

APRI Thresholds for Fibrosis and Cirrhosis: Updated Treatment Criteria

Based on the 2024 WHO guidelines for chronic hepatitis B, treatment is now recommended when APRI >0.5 (indicating significant fibrosis ≥F2) or APRI >1.0 (indicating cirrhosis), representing a major shift from the outdated threshold of APRI >2.0 that missed at least 50% of cirrhosis cases. 1

Current Evidence-Based APRI Cutoffs

For Significant Fibrosis (≥F2)

• APRI >0.5: This lower threshold identifies most adults with significant fibrosis requiring treatment

  • Sensitivity: 72.9% (70.2–75.5%)
  • Specificity: 64.7% (61.0–68.2%)
  • This cutoff prioritizes minimizing false negatives (missing only 6.8% of patients with significant fibrosis) while accepting more false positives (26.2%) 1

• APRI >0.7: Alternative threshold for significant fibrosis

  • Provides slightly higher specificity but lower sensitivity 1

For Cirrhosis (F4)

• APRI >1.0: Lower threshold to identify most adults with cirrhosis needing priority treatment

  • Sensitivity: 59.4% (53.2–65.2%)
  • Specificity: 73.9% (70.1–77.4%)
  • At 5% cirrhosis prevalence: 24.7% false positives but only 2.1% false negatives 1

• APRI >2.0: Higher threshold for cirrhosis (the OLD 2015 WHO guideline cutoff)

  • Sensitivity: 29.3% (23.5–35.8%)
  • Specificity: 88.7% (86.1–90.8%)
  • This threshold is now considered obsolete as it misses >50% of cirrhosis cases 2, 1

When NOT to Treat Based on APRI Alone

APRI ≤0.5 generally indicates absence of significant fibrosis and treatment may be deferred, though this should be considered alongside other clinical factors (HBV DNA levels, ALT, clinical evidence of liver disease, age, family history of HCC). 1

Important Caveats:

1. AST Level Impact: The conventional cutoffs have high misclassification rates when AST is elevated due to acute inflammation. Higher AST levels require adjusted APRI thresholds:

   • AST ≤37 IU/L: APRI cutoff 0.6 for cirrhosis
   • AST 37-74 IU/L: APRI cutoff 1.1 for cirrhosis
   • AST 74-148 IU/L: APRI cutoff 2.2 for cirrhosis
   • AST >148 IU/L: APRI cutoff 3.4 for cirrhosis 3

2. Normal ALT Patients: In chronic hepatitis B patients with normal ALT, even lower cutoffs may be needed:

   • APRI ≤0.21 can exclude cirrhosis with 97% sensitivity and 95.6% NPV
   • The conventional cutoffs had 77.6% misclassification rate in this population 4

3. False Positives: APRI uses AST, which can be elevated by acute hepatitis, hemolysis, or other non-fibrotic liver injury, leading to overestimation of fibrosis stage 2

Dual Cutoff Strategy (Rule-Out/Rule-In Approach)

For optimal diagnostic accuracy, use dual cutoffs:

• Significant Fibrosis: APRI ≤0.5 (rule out) vs APRI >1.5 (rule in)

  • Values between 0.5-1.5 are indeterminate and require additional testing (FibroScan, FIB-4, or liver biopsy) 2

• Cirrhosis: APRI ≤1.0 (rule out) vs APRI >2.0 (rule in)

  • Values between 1.0-2.0 require additional assessment 2, 1

Clinical Algorithm

1. Calculate APRI = [(AST/ULN) × 100] / Platelet count (10⁹/L)

2. For Treatment Decisions in Chronic Hepatitis B:

   • APRI >0.5 OR FibroScan >7.0 kPa → Treat (significant fibrosis ≥F2)
   • APRI >1.0 OR FibroScan >12.5 kPa → Priority treatment (cirrhosis F4)
   • APRI ≤0.5 AND no clinical cirrhosis → Consider monitoring without immediate treatment 1

3. Adjust interpretation based on:

   • AST level (use stratified cutoffs if AST elevated) 3
   • ALT level (lower cutoffs if ALT normal) 4
   • Clinical context (age, HBeAg status, family history)

The paradigm shift from APRI >2.0 to APRI >0.5 for treatment initiation reflects the WHO's 2024 decision to prioritize early treatment and reduce liver-related mortality, accepting higher false-positive rates to minimize missing patients who need therapy. 1